SOURCE: slp3D

May 10, 2005 07:15 ET

Reminder - OR-Live.com presents: Percutaneous Cryoablation -- A Minimally Invasive Alternative to Ease Pain in Patients With Advanced Cancer

Live Webcast: May 10th, 2005, at 6 PM EDT (22:00 UTC)

HARTFORD, CT -- (MARKET WIRE) -- May 10, 2005 -- For cancer patients with certain types of inoperable tumors of the lung, liver, kidney or bone, percutaneous cryoablation is an option for easing pain. Using miniaturized probes that glide through the skin, Hartford Hospital physicians inject argon gas into the tumor to freeze it to its margins. They watch the resultant ice ball form through CT and ultrasound imaging, and control its growth to protect nearby structures. A 28-minute freeze-thaw-freeze-thaw cycle destroys the tumor. Radiologists at Hartford Hospital will perform the procedure in a live webcast on May 10th at 6 o'clock pm ET on www.OR-Live.com.

John Straub, MD Professor and Chair of Neurosurgery, explains, "Percutaneous cryoablation has given us a modality for treating previously untreatable tumors with a reasonable degree of success and has given us a modality for providing pain relief in a certain patient population that has been relegated to narcotics and suffering. It has provided us with a way to extend life in people who have a terminal disease and (desire) some time to enjoy their last years."

The probes used in the percutaneous cryoablation procedure do not insert gas into the body, the gas flows through the probes and become very cold, colder than -150 Celsius at the tip and create an ice ball by freezing the fluid in the cells.

CT-guided procedures are generally appropriate for patients that are not candidates for surgery (only 10% of patients with a liver tumor are surgical candidates~ 35,000 primary liver cancer, over 130,000 colorectal carcinoma patients annually, with about 75% that metastasize to the liver, and about 10% of lung cancer patients are candidates for surgery of the over 1,000,000 patients that are diagnosed each year). A great number of patients don't respond to external beam radiation treatment for the management of bone metastases, who may also be candidates for cryoablation.

Viewers of this live broadcast will have the ability to send questions direct to the operating theatre for an on-camera response by Dr. Straub and his team.

Educational funding for this CME webcast is provided by a grant from Endocare, Inc (OTC: ENDO).

Visit http://www.or-live.com/hartfordhospital/1350 now to view a program preview and doctor's comments. A VNR is available at http://www.or-live.com/rams/hah-1350-mkw-q.ram

Contact Information

  • Contact:
    Alex Fraser
    Director of Marketing
    slp3D, Inc
    860-953-2900 x 214